OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Ending ‘Magical Thinking’ in Compounding
Consistent product quality requires a clear understanding of the essence of CGMPs. Experts fear that the message is not always getting through to compounders.
Pharmaceutical compounding recalls the earliest days of medicine making, when the mortar and pestle, and variability, were the rule. Since that time, and the establishment of the United States Pharmacopeia (USP) and FDA in the United States, the field has come a long way.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
October 2020
Pages: 46-51
Citation
When referring to this article, please cite it as A. Shanley, “Ending ‘Magical Thinking’ in Compounding," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).
